Innovating Cell Culture
PL BioScience produces human platelet lysate (HPL) as a next-generation growth supplement for cell and gene therapy. Their GMP-compliant, xeno-free media products support safer, scalable manufacturing of therapeutic cells. PL offers a full range of powerful alternative to animal-derived inputs, addressing a growing industry demand
The industry can’t scale on animal serum
Advanced therapy developers still depend on animal-derived media, like fetal bovine serum (FBS) that pose ethical, safety, and regulatory hurdles. As the field moves toward industrial-scale manufacturing, the need for consistent, human-relevant inputs has never been greater.
Xeno-Free. GMP-ready. built for tomorrow’s therapies.
PL BioScience’s ELAREM™ platform of hPL-based media delivers performance and safety with human relevance. Their GMP manufacturing, batch consistency, and regulatory alignment make them the partner of choice for therapy developers ready to scale from bench to bedside.
Guided by experience. Positioned for scale
AVANT BIO brings hands-on expertise in scaling media platforms for advanced therapies. Partner Reinhard Vogt, a global leader in business growth within cell culture, works closely with PL BioScience to support global expansion, strategic partnerships, and regulatory readiness.
The industry can’t scale on animal serum
Advanced therapy developers still depend on animal-derived media, like fetal bovine serum (FBS) that pose ethical, safety, and regulatory hurdles. As the field moves toward industrial-scale manufacturing, the need for consistent, human-relevant inputs has never been greater.
Xeno-Free. GMP-ready. built for tomorrow’s therapies.
PL BioScience’s ELAREM™ platform of hPL-based media delivers performance and safety with human relevance. Their GMP manufacturing, batch consistency, and regulatory alignment make them the partner of choice for therapy developers ready to scale from bench to bedside.
Guided by experience. Positioned for scale
AVANT BIO brings hands-on expertise in scaling media platforms for advanced therapies. Partner Reinhard Vogt, a global leader in business growth within cell culture, works closely with PL BioScience to support global expansion, strategic partnerships, and regulatory readiness.